Posts

Showing posts with the label Cholangiocarcinoma (Bile Duct Cancer)

Cholangiocarcinoma (Bile Duct Cancer) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Cholangiocarcinoma (CCA) comprises a diverse range of bile duct neoplasms, ranking as the second most prevalent hepatic cancer after hepatocellular carcinoma. It is classified into intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA), with the latter encompassing perihilar cholangiocarcinoma (pCCA or Klatskin tumor) and distal cholangiocarcinoma (dCCA). Symptoms of cholangiocarcinoma encompass jaundice, dark urine, clay-colored stools, abdominal pain, fever, pruritus, nausea, vomiting, and unintended weight loss. Risk factors for this condition include: 1.        Primary sclerosing cholangitis 2.        Chronic ulcerative colitis 3.        Bile duct cysts 4.        Infection with the Chinese liver fluke parasite Staging of cholangiocarcinoma utilizes the TNM system, evaluating tumor size (T), involvement of lymph nodes (N), and presence of ...

Cholangiocarcinoma (Bile Duct Cancer) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
 Cholangiocarcinoma, also called bile duct cancer, is a rare form of cancer that arises from the malignant transformation of cells in the bile ducts. There are two main types of cholangiocarcinoma: intrahepatic, which originates in the bile ducts within the liver, and extrahepatic, which occurs in the bile ducts outside the liver. The latter is classified into perihilar and distal bile duct cancer based on location. The signs and symptoms of cholangiocarcinoma include jaundice, dark urine, clay-colored stools, abdominal pain, fever, itchy skin, nausea and vomiting, and unexplained weight loss. It is important to consult a physician if these symptoms are present. The risk factors for cholangiocarcinoma include primary sclerosing cholangitis, chronic ulcerative colitis, bile duct cysts, and infection with the Chinese liver fluke parasite. The staging of cholangiocarcinoma is determined using the TNM system, which assesses the size of the tumor (T), the number of affected lymph nodes ...